Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to see how effective the investigators' optimized magnetic resonance spectroscopy (MRS) sequence in quantifying hepatic triglyceride content (HTGC) to enhance MRS as a diagnostic tool in non-alcohol fatty liver disease (NAFLD).
| Condition |
|---|
|
Liver Diseases |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | MRS Validation Study of Hepatic Triglyceride Content in Non-alcoholic Fatty Liver Disease (NAFLD)Subjects Pre- and Post-Prandial |
- The Reproducibility of the Hepatic Triglyceride Content Measurement by MRS. [ Time Frame: 6 months ] [ Designated as safety issue: No ]We compared three 1H-Magnetic Resonance Spectroscopy sequences: A Standard Siemens sequence, and an optimized sequence with either breath-holds or free-breathing. Repeat scans were done with the subject briefly removed from and returned to the scanner between scans. The results given are coefficients of variation of the triglyceride signal divided by the water signal.
- The Hepatic Triglyceride Content Pre- and Post-prandial. [ Time Frame: after a 12 hour fast and 2 hours post-prandial ] [ Designated as safety issue: No ]We compared the intrahepatic triglyceride content in subjects after a 12 hour fast and 2 hours after eating a high fat, high carbohydrate meal. The measure reported here is for the pre and post prandial results given as the ratio of triglyceride signal to water signal. After showing its reliability, we chose to use the results from the optimized breath-hold sequence.
- T2 (Spin-spin Relaxation Time) Ratios of Triglyceride/Water [ Time Frame: baseline cross-sectional measurements ] [ Designated as safety issue: No ]T2 (spin-spin relaxation time) ratios of triglyceride/water using optimized PRESS sequences
| Enrollment: | 14 |
| Study Start Date: | June 2009 |
| Study Completion Date: | March 2010 |
| Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
NAFLD
Non-diabetic, obese with diagnosed NAFLD (HTGC greater or equal to 5.5%)
|
|
Non-NAFLD
Non-diabetic, obese with no previous diagnosis of NAFLD
|
Detailed Description:
One way to gauge MRS as an effective diagnostic tool is by looking at the reproducibility of the liver fat measurements on subjects by calculating the coefficient of variation (CV). This study assesses the modified MRS sequence, using both breath holds and free breathing. The HTGC levels are measured twice in the same individuals on two independent events separated by 10 minutes. Subjects are then given a high fat, high carbohydrate meal of Pizza Hut pizza, Pepsi, and Oreo cookies. Two hours after eating the meal, the subjects return to the scanner and repeat all MRS scans.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
St. Louis community
Inclusion Criteria:
- Obese
Exclusion Criteria:
- Diabetes
- Pregnant
Contacts and Locations| United States, Missouri | |
| Barnes Jewish Hospital | |
| St. Louis, Missouri, United States, 63110 | |
| Principal Investigator: | Samuel Klein, M.D. | Washinton University in St. Louis |
More Information
No publications provided
| Responsible Party: | Samuel Klein, M.D., Washington Univeristy in St. Louis |
| ClinicalTrials.gov Identifier: | NCT00940537 History of Changes |
| Other Study ID Numbers: | 06-0229 |
| Study First Received: | July 14, 2009 |
| Results First Received: | April 13, 2010 |
| Last Updated: | July 2, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Washington University School of Medicine:
|
Obese MRS hepatic triglyceride content MR spectroscopy |
Additional relevant MeSH terms:
|
Fatty Liver Liver Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013